IBS Pain vs Discomfort: Why the Distinction Matters Clinically

If you have IBS, you have probably been asked some version of "is it pain, or is it more like discomfort?" by a clinician who then made a meaningful decision based on your answer. The question is not idle. The Rome IV criteria, published in 2016, replaced the older "abdominal pain or discomfort" wording with "recurrent abdominal pain" specifically because the discomfort half of the phrase had become a diagnostic problem. This guide walks through why the change happened, what counts as pain in the new framework, what the common IBS pain patterns suggest mechanistically, what discomfort-only presentations probably are if they are not IBS, how clinicians measure pain severity, why visceral hypersensitivity is the layer most patients have not had explained to them, and what genuinely helps IBS pain across the available mechanism categories.

The Rome criteria are the international consensus framework for diagnosing functional GI disorders. They are revised roughly every decade by a panel of researchers and clinicians who weigh new evidence, real-world clinical experience, and the implications of how the criteria are being used in trials and in practice. Rome III, published in 2006, defined IBS as "recurrent abdominal pain or discomfort at least three days per month in the last three months, associated with two or more of the standard stool-related criteria." Rome IV, published in 2016, made several changes. The most consequential was the removal of "or discomfort" from the pain criterion and a tightening of the frequency requirement to at least one day per week.

The change was not stylistic. It was a deliberate response to two problems that had emerged in the decade since Rome III. The first was that "discomfort" was being interpreted differently across clinicians, across patients, and across cultures and languages. The Rome committee surveyed clinicians and patients about what they meant by "discomfort" and got back a range of answers spanning bloating, fullness, urgency, queasiness, pressure, mild ache, and several other sensations. There was no single referent. The diagnostic criterion was effectively measuring different things in different hands. The second problem was that this vagueness was producing inconsistent IBS prevalence estimates across populations, inflating the apparent burden of disease in some and missing genuine cases in others.

What the committee chose to do

The Rome IV committee made the call to keep the criterion focused on a single, more reliably reported sensation: pain. Pain is also more reliably linked to the underlying mechanism that distinguishes IBS from related disorders, which is visceral hypersensitivity (the central amplification of normal gut signals into conscious pain). Discomfort is a softer signal that can be generated by many mechanisms, including ones that are not part of the IBS mechanism set. By restricting the criterion to pain, Rome IV produced a tighter, more biologically coherent definition.

The trade-off was acknowledged openly. Some patients who would have met Rome III with discomfort-dominant presentations no longer met Rome IV. These patients were not abandoned. They were redirected to other Rome IV diagnoses that are better matches for their actual physiology: functional bloating for bloating without pain, functional diarrhea for loose stools without pain, functional dyspepsia for upper-abdominal symptoms, and so on. Each of these has its own evidence-based management approach. Getting the right Rome IV label gets you the right plan, which is the point.

Why pain is the more useful diagnostic anchor

Pain has several advantages as a diagnostic anchor over discomfort. It is more reliably reported. Patients can usually distinguish pain from non-pain sensations even when they cannot precisely describe pain quality. It is more reliably remembered, particularly when it is recent or recurrent. It correlates better with measurable physiological abnormalities, particularly visceral hypersensitivity on barostat distension testing. It correlates better with quality-of-life impact, healthcare utilisation, and treatment response in trials. And it is more consistent across cultures and languages, which matters for a criterion intended for global use.

None of this means discomfort is unreal or unimportant. Discomfort is a meaningful experience and worth taking seriously. The point is that for the specific job of defining a coherent diagnostic category, pain does the job better. For a deeper treatment of how all the Rome IV criteria fit together, see the page on the actual diagnostic criteria for IBS.

What this means for your label specifically

If you were diagnosed with IBS before 2016 and the workup was solid at the time, your label is probably still accurate, particularly if pain was a documented part of your presentation. If your original presentation was discomfort-dominant without a clear recurrent pain component, it may be worth a conversation with your clinician about whether one of the related Rome IV diagnoses fits better. This is not a downgrade. The reason it matters is that treatment selection differs, and a more precise label opens up management approaches that may not have been on the table under the broader IBS umbrella.

The Rome IV pain criterion has three parts that all need to be met. Understanding each one is the difference between a label that is technically wrong and one that opens the right treatment doors.

Part one: recurrent abdominal pain at least one day per week

The frequency threshold is at least one day per week with abdominal pain, looking back over the last three months. This is more frequent than the Rome III threshold of three days per month, and it was tightened deliberately. The reason is that occasional abdominal pain (a few times a year, around specific food triggers or specific stress events) is so common in the general population that including it as IBS would inflate prevalence beyond clinical usefulness. The weekly threshold separates IBS as a chronic condition from incidental abdominal pain.

In practice, most patients who actually have IBS hit this threshold easily and often exceed it considerably, with pain on most days or constant low-grade pain punctuated by flares. The threshold is not a high bar. It is a floor designed to keep the diagnosis specific.

Part two: pain associated with at least two of three stool features

The pain alone is not enough. Rome IV requires that the pain be related to bowel function in at least two of three ways: pain that is associated with defecation (it changes around the time of a bowel movement, either better or worse), pain that is associated with a change in stool frequency (more or fewer bowel movements during pain episodes), or pain that is associated with a change in stool form (looser or harder stools during pain episodes). Note the wording: "associated with" includes both improvement and worsening. Some patients have pain that is relieved by a bowel movement; others have pain that is triggered or worsened by one. Both count.

The reason for this requirement is that it links the pain to the gut specifically. Abdominal pain that is not related to bowel function is more likely to have a non-IBS source (gynecological, urological, musculoskeletal, biliary, vascular, or one of the rarer abdominal pain syndromes). Anchoring the pain to bowel function increases the probability that the underlying mechanism is the gut-brain interaction set that defines IBS rather than something else.

Part three: symptoms onset at least six months before diagnosis

The third part is that symptoms must have been present for at least six months before the diagnostic threshold is met. This is the chronicity requirement. New abdominal pain of less than six months duration, even if it meets the frequency and stool-association criteria, is not yet IBS. The six-month window is meant to exclude post-infectious GI states that are still resolving, transient stress-related episodes, and early presentations of conditions that have not yet declared themselves. Many cases that resolve within six months would have been incorrectly labelled as IBS under shorter chronicity requirements, leading to unnecessary anxiety and management.

What counts as pain quality-wise

Rome IV does not specify a pain quality. Cramping, aching, sharp, dull, gripping, stabbing, burning, pressure crossing into pain, and several other descriptors all count as long as the underlying experience is recognisable to the patient as pain rather than as a milder sensation. Patients sometimes worry that their pain "does not count" because it is not sharp or because they call it cramping rather than pain. This is not how the criterion works. If you experience the sensation as painful and severe enough to register clinically, and it meets the frequency and stool-association requirements, it counts.

Where patients sometimes get into trouble is the opposite direction: describing a sensation as pain when on careful questioning it is actually fullness, pressure, or bloating that does not really cross the pain threshold. This is one reason a careful clinical interview matters. The label depends on getting the sensation right, not just on the patient using the word "pain."

IBS pain is not one thing. Patients describe several patterns that map, at least loosely, to different mechanism contributions. None of these patterns is diagnostic in isolation, but recognising the dominant pattern in your own presentation can guide which interventions are most likely to help and which red flags to take seriously.

Postprandial cramping (gastrocolic-amplified)

A very common pattern is cramping that comes on within 30 to 90 minutes after a meal, often diffuse but sometimes lower-quadrant, and that builds in waves before easing. The mechanism is the gastrocolic reflex (the colon's normal motor response to food entering the stomach) being amplified by visceral hypersensitivity. In healthy people, the gastrocolic reflex produces a mild urge to defecate after a meal and minimal pain. In IBS, the same neural signal is amplified centrally into pain. The pattern is more pronounced after large meals, fatty meals, and meals high in fermentable carbohydrates (FODMAPs) that produce more colonic distension.

Mechanism-targeted interventions for this pattern include antispasmodics (peppermint oil before meals, hyoscine), portion-size moderation, FODMAP-aware eating, and brain-gut therapies that retrain the central amplification. Heat applied to the abdomen during episodes is an underused acute strategy that helps a meaningful subset of patients.

Sharp lower-left quadrant (sigmoid distension)

A sharp or stabbing pain located specifically in the lower-left quadrant is often a sigmoid colon distension pattern. The sigmoid is the S-shaped segment of colon just before the rectum, and it is a common location for gas trapping and high-pressure contractions in IBS. The pain is usually transient, sometimes severe, and often relieved by passing gas or having a bowel movement. It can also be triggered by sitting in particular positions that mechanically compress the sigmoid.

This pattern responds to gas-reducing strategies (FODMAP awareness, slower eating to reduce air swallowing, addressing constipation that worsens gas trapping), antispasmodics, and where indicated specific motility interventions. It rarely needs imaging unless the pattern changes or red flags develop.

Diffuse aching that improves after BM

A diffuse, dull, aching pain across the lower abdomen that builds over hours and improves after a bowel movement is one of the most classic IBS patterns. It maps to a combination of motility dysregulation and visceral hypersensitivity, with the BM-relief signal being the strongest single piece of evidence that the pain is gut-related rather than from another abdominal source.

This pattern often responds well to a combination approach: dietary first-line where indicated (low-FODMAP trial, fibre adjustment based on subtype), brain-gut therapy for the central component, and where pain is severe or persistent, low-dose tricyclic antidepressants (which are used at sub-antidepressant doses for their visceral pain modulation rather than for mood).

Pain that wakes you from sleep

This pattern is a red flag and is not typical IBS. Healthy gut nociception generally follows the same diurnal quietness as the rest of the gut overnight, and IBS pain typically clusters around meals, mornings, or stress events rather than waking you from sleep. Consistent nocturnal awakening pain warrants a workup that includes inflammatory markers, fecal calprotectin to screen for inflammatory bowel disease, abdominal imaging where indicated, and sometimes endoscopy or colonoscopy depending on the pattern.

Conditions that can present with nocturnal abdominal pain and that should not be missed include inflammatory bowel disease (Crohn disease, ulcerative colitis), peptic ulcer disease, biliary pathology (especially after fatty evening meals), pancreatic disease, and less commonly intra-abdominal malignancy. Most workups for nocturnal pain still come back negative, which is reassuring. The point is that the workup should happen rather than being assumed unnecessary because IBS is the working label.

Right-sided constant pain

Pain that is consistently localised to the right side, particularly the right lower quadrant, and that is constant rather than fluctuating is another pattern that warrants workup beyond IBS. The differential includes appendicitis (usually acute and progressive rather than chronic), Crohn disease (which has a predilection for the terminal ileum and right colon), ovarian pathology in patients with ovaries, kidney pathology, and several rarer conditions. Chronic constant right-sided pain that has not been worked up should not be assumed to be IBS even if there is a prior IBS label.

The general rule that experienced functional GI clinicians follow is that IBS pain fluctuates, moves around (or is at least not rigidly fixed in one location for months), changes character with bowel movements and meals, and has triggers that the patient can usually identify with careful tracking. Pain that violates this pattern (constant, fixed location, no relation to gut function, no identifiable triggers) deserves a fresh look even in someone with established IBS. For more on this specific question, see the page on when pain pattern suggests something else.

One of the most useful consequences of the Rome IV change is that discomfort-only presentations now have better-matched homes than the broad IBS umbrella. If you have chronic GI symptoms that are real and bothersome but do not include a clear recurrent pain component, you are not asymptomatic and you are not exaggerating. You probably fit one of the related Rome IV diagnoses, each of which has its own evidence-based management.

Functional bloating

Functional bloating describes recurrent bloating or visible distension as the dominant symptom, without sufficient pain to meet IBS criteria and without other features that would point to a different diagnosis. It is common, often under-recognised, and tends to get conflated with IBS in clinic when patients describe their symptoms loosely. The mechanisms overlap with IBS (visceral hypersensitivity, motility regulation, sometimes microbial fermentation patterns), but the symptom emphasis is different and the management leans more on dietary moves, posture and core engagement work, motility-targeted approaches, and addressing constipation if present.

Functional diarrhea

Functional diarrhea describes recurrent loose or watery stools as the dominant symptom, occurring in at least 25 percent of stools, without sufficient pain to meet IBS-D criteria. It is distinct from IBS-D specifically because the pain component is missing. The differential includes bile-acid malabsorption (which is more common than historically appreciated and has specific treatment), microscopic colitis (especially in older patients or those on certain medications), small intestinal bacterial overgrowth in some cases, and several other patterns. The workup and management differ from IBS-D in important ways, which is why getting the right Rome IV label matters.

Functional dyspepsia

Functional dyspepsia describes upper-abdominal symptoms (early satiety, postprandial fullness, epigastric pain or burning) as the dominant pattern, without meeting IBS criteria. There is meaningful overlap between IBS and functional dyspepsia in many patients (you can have both), but functional dyspepsia has its own subgroups (postprandial distress syndrome, epigastric pain syndrome) and its own first-line management that includes proton pump inhibitor trials in some cases, prokinetic agents, and brain-gut therapies. Getting the upper-abdominal symptom set named correctly opens up management options that are not typically deployed for lower-abdominal IBS.

Why this is not a "lesser" diagnosis

There can be a temptation, when a diagnostic label gets refined, to feel that the new label is somehow less serious than the old one. This is the wrong framing. Functional bloating, functional diarrhea, and functional dyspepsia are real Rome IV diagnoses with their own evidence base. They are not "IBS-lite." In some patients they cause as much functional impact as IBS and require the same level of clinical attention. The reason the labels matter is that the management approaches differ in specific ways, and matching the right label to the right patient produces better outcomes than treating everything as generic IBS.

If your previous clinician applied an IBS label loosely and the description fits one of the related disorders better, this is worth raising at your next appointment. The change in label may open management options (different medications, different dietary emphasis, different referral pathways) that were not on the table under the previous frame.

Once a diagnosis is in place, the clinical question shifts from "is this IBS?" to "how severe, in which dimensions, and is treatment moving the needle?" Two instruments dominate IBS pain measurement in both clinic and research. Knowing how they work helps you have a more useful conversation with your clinician and lets you track your own response to interventions in a way that captures the real picture rather than a snapshot bias.

The IBS Symptom Severity Score (IBS-SSS)

The IBS-SSS is a 0-to-500 composite score that includes five components: severity of abdominal pain (0 to 100 visual analog scale), number of days with pain in the last 10 days (0 to 100), severity of abdominal distension (0 to 100), dissatisfaction with bowel habit (0 to 100), and interference of IBS with daily life (0 to 100). The five components are summed to produce the total. Pain contributes a major share, both directly through the pain severity component and indirectly through the impact-on-life component which is heavily driven by pain in many patients.

The standard severity bands are: under 75 indicates remission, 75 to 175 indicates mild IBS, 175 to 300 indicates moderate IBS, and above 300 indicates severe IBS. In trials, a clinically meaningful response is typically defined as a 50-point reduction from baseline or a 50 percent improvement from baseline, depending on the trial protocol. The IBS-SSS is the most commonly used outcome measure in IBS trials and is also the score behind the response rates quoted from Miller 2015 (PMID 25736234), Peters 2016 (PMID 27397586), Hasan 2019 (PMID 30702396), and Everitt 2019 (PMID 30765267).

The Visual Analog Scale (VAS)

The VAS is much simpler: a 0-to-10 single-item rating of pain in the moment or averaged over a recent window (typically the last 24 hours or the last week). It is fast to use, easy to track in a symptom diary, and surprisingly informative when collected daily over weeks rather than as a one-off snapshot. A patient who fills out a VAS every evening for a month gives their clinician a much richer picture of pain pattern and severity than a single appointment recall ever can.

The VAS is also the simplest tool for tracking your own response to a new intervention. Pick a baseline window of two to four weeks before starting (low-FODMAP, GDH, a new medication, a lifestyle change), record daily VAS evenings, then continue through the intervention period. The shape of the curve over time gives you and your clinician a much clearer answer about whether the intervention is working than impressionistic recall.

Frequency multiplied by intensity matters more than peak

One of the most useful clinical insights from both instruments is that frequency multiplied by intensity gives a more useful picture than peak intensity alone. A patient who reports a worst-day VAS of 9 but only has pain on three days per month is in a different clinical situation than a patient who reports a worst-day VAS of 6 but has pain on twenty-five days per month. The second patient often suffers more functionally despite the lower peak number. Treatment decisions should weight the frequency component, not just the worst-day memory.

This is also why a symptom diary kept for two to four weeks tends to give a much more useful clinical picture than a single appointment recall. Recall is biased toward worst days, most recent days, and emotionally salient episodes. Daily tracking captures the actual pattern. If you are about to start a structured treatment program (low-FODMAP, GDH, a new medication trial), keeping a daily diary for two weeks before and during the intervention is one of the highest-yield things you can do.

If you take only one mechanism away from this page, make it this one. The pain you feel in IBS is not generated by abnormal events in the gut. It is generated by normal events in the gut being amplified into conscious pain by a sensitised visceral nervous system. This is the difference between IBS pain and structural-disease pain, and understanding it changes how the available treatments make sense.

What barostat distension testing actually shows

Barostat distension is a research technique in which a small balloon is positioned in the rectum or sigmoid colon and then inflated in controlled increments while the patient reports the volume at which they first feel a sensation, the volume at which they feel discomfort, and the volume at which they feel pain. In healthy controls, these thresholds cluster in fairly predictable ranges. In IBS patients, the pain threshold consistently sits at lower volumes than in healthy controls. The same physical stimulus produces conscious pain in IBS where healthy people feel little or nothing.

This is the core operational definition of visceral hypersensitivity, and it is one of the most replicated findings in IBS research. It is not in dispute. The implication is that the gut signals themselves (contractions, distension, gas movement) may be entirely normal in many IBS patients. The amplification at the spinal cord, brainstem, and brain levels is what produces the symptom. For more on this mechanism specifically, see the page on the gut-nerve sensitivity that drives pain.

What functional brain imaging adds

Functional MRI studies in IBS patients during gut distension protocols show altered activation patterns in central pain processing regions, particularly the anterior cingulate cortex, insula, and prefrontal cortex. The activation is not just larger in some regions; it is qualitatively different in the network architecture, suggesting that the brain processes gut signals through different circuits in IBS than in healthy controls. This is consistent with the broader concept of central sensitisation, in which repeated nociceptive input rewires central processing toward a more reactive state.

The clinical implication is that interventions that act centrally have a real biological target. They are not just placebo or distraction. Brain-gut therapies (gut-directed hypnotherapy, CBT for IBS) and central neuromodulators (low-dose tricyclics, certain SNRIs) are working on the layer that is actually generating the symptom. For a broader treatment of how this fits into the multifactorial IBS picture, see the page on underlying mechanisms in IBS.

The treatment implication: numb the perception or change the volume

Once you accept the visceral hypersensitivity layer, the treatment options sort themselves into two broad categories. The first category targets the volume of the gut signal. This includes dietary interventions (low-FODMAP reduces fermentation and therefore distension), antispasmodics (reduce muscular cramping that produces nociceptive input), addressing constipation (reduces colonic distension), and addressing gas patterns. The second category targets the central perception of the signal. This includes brain-gut therapies (GDH, CBT for IBS), central neuromodulators (low-dose tricyclics, SNRIs), and to a lesser extent autonomic regulation work.

Both categories work. The choice of which to deploy first depends on patient phenotype, preference, and previous response to other interventions. Where dietary first-line approaches have produced partial response that has plateaued, adding a central-acting intervention often shifts the picture meaningfully. Where dietary approaches are not feasible (eating disorder history, social context, sustainability concerns), starting with a central-acting intervention can be appropriate. Peters 2016 (PMID 27397586) is the head-to-head equivalence trial that established gut-directed hypnotherapy as comparable to low-FODMAP on outcome, with each intervention having different non-symptom trade-offs (cost, ongoing effort, dietary restriction burden).

Why dietary interventions miss this layer when it dominates

A patient whose symptoms are dominated by the central amplification rather than by the volume of gut signal can do everything right on a low-FODMAP diet and see only modest improvement. The diet is reducing the input, but the amplifier is still set high. This is the patient profile for whom adding a brain-gut therapy or a central neuromodulator often produces the disproportionate improvement that previous dietary attempts did not deliver. It is also the patient profile for whom continuing to escalate the dietary approach (more restrictions, longer elimination phases, additional probiotic protocols) produces diminishing returns, because the bottleneck has shifted from peripheral input to central processing.

This is also one of the reasons that clinicians who specialise in functional GI care increasingly think in terms of layered phenotype-matched plans rather than sequential first-line trials. The patient whose dominant mechanism is central amplification often benefits from starting with central-acting interventions and adding dietary moves where they help, rather than the reverse. The phenotype work that distinguishes these patients is one of the most useful skills in modern functional GI practice.

The interventions below are organised by mechanism rather than by a single ranking. Different patients with different dominant mechanisms get different mileage from each option, and the most useful clinical move is matching the intervention to the dominant pain pattern rather than running everyone through the same algorithm.

Antispasmodics: reduce the muscular cramping component

Antispasmodics reduce smooth-muscle contraction in the gut wall and are a reasonable first-line option for the cramping component of IBS pain. The two with the most evidence and the cleanest safety profile are peppermint oil (taken in enteric-coated capsules so the active components reach the small intestine and colon rather than dissolving in the stomach) and hyoscine (an anticholinergic available over the counter or by prescription depending on the formulation). Both work best taken before anticipated triggers (a meal, a stressful event) rather than waiting for pain to develop.

Side effects are generally mild. Peppermint oil can cause heartburn in some patients (mitigated by the enteric coating, but not always fully). Hyoscine can cause dry mouth, mild urinary hesitancy, or blurred vision at higher doses, with more concerning effects in older patients or those on other anticholinergic medications. Neither is appropriate as a long-term continuous strategy without clinical oversight, but as situational tools they have a real evidence base for IBS cramping pain.

Low-dose tricyclics and SNRIs: central pain modulation

Tricyclic antidepressants (amitriptyline, nortriptyline) and certain SNRIs (duloxetine in some patients) are used in IBS at doses well below their antidepressant doses, and the mechanism for IBS pain is visceral pain modulation rather than mood effect. These agents have RCT-grade evidence for moderate to severe IBS pain that has not responded to first-line approaches, and they work by modulating central pain processing pathways through descending inhibitory mechanisms.

The trade-off is the side-effect burden. Tricyclics can cause dry mouth, constipation (which can be useful in IBS-D and counterproductive in IBS-C), drowsiness, and rarely cardiac effects in vulnerable patients. SNRIs can cause nausea, sleep disruption, and have their own discontinuation profile. The decision to start a central neuromodulator is appropriate for a prescriber who can monitor response and adjust, and is not a casual self-medication option. Where they fit, they often produce meaningful pain reduction that justifies the burden.

Gut-directed hypnotherapy: changes visceral pain perception over a course

Gut-directed hypnotherapy on the Manchester Protocol is a structured 8 to 12 session intervention that uses suggestion and imagery to retrain visceral signal processing. The mechanism is central, not peripheral. Functional imaging studies in patients who respond show altered activation in central pain processing regions, and the trained relaxation response that builds across sessions persists between them and after the course ends.

The evidence base for IBS pain specifically is part of the broader IBS efficacy data. Miller 2015 (PMID 25736234) reported a 76 percent response rate in 1,000 consecutive refractory IBS patients in real-world clinic data, with response defined as at least a 50 percent improvement on a validated symptom score that includes pain as a major component. Peters 2016 (PMID 27397586) established equivalence to the low-FODMAP diet on symptom outcomes including pain in a randomised controlled trial. Hasan 2019 (PMID 30702396) reported durability of response at 5+ year follow-up. Where a patient has a meaningful central amplification component to their pain, GDH is one of the better-evidenced options. The honest framing is that it is one tool in the toolkit, not a universal cure, and works best as part of a layered plan. For more, see the page on GDH for pain modulation.

CBT for IBS: cognitive reframing of pain catastrophizing

Cognitive behavioural therapy adapted for IBS is the other major brain-gut therapy with RCT-grade evidence. Everitt 2019 (PMID 30765267) reported clinically significant IBS symptom improvement in 71 percent of patients who received therapist-delivered CBT in a large UK trial. CBT for IBS targets the cognitive patterns that maintain symptom amplification, particularly pain catastrophizing (the tendency to interpret pain as more dangerous or more severe than it physiologically is, which itself amplifies the central pain response).

CBT for IBS and gut-directed hypnotherapy are both in major guidelines (NICE, BSG) as evidence-based brain-gut therapy options for IBS. Trial designs differ, so they cannot be ranked directly against each other. The honest framing is that both are valid options with somewhat different mechanisms (cognitive reframing versus visceral perception retraining) and somewhat different patient fits. Patients who score high on hypnotic suggestibility tend to respond well to GDH; patients with prominent cognitive distortions around pain or significant comorbid anxiety may fit better with CBT. Many patients would respond to either, and the choice often comes down to access, cost, and personal preference.

Heat: underused for cramping

Direct heat applied to the abdomen during pain episodes activates TRPV1 receptors in the skin and underlying tissue, which engage descending inhibitory pain pathways and can reduce visceral pain perception. The mechanism is the same one used by topical capsaicin in some chronic pain conditions. A heating pad, hot water bottle, or warm bath is a low-cost, no-side-effect acute management strategy that helps a meaningful subset of IBS patients with cramping pain. It is underused in clinical advice and worth deploying as a first acute intervention before reaching for medication.

What does NOT help long-term: NSAIDs and opioids

Two categories of pain medication are actively counterproductive for IBS pain. Non-steroidal anti-inflammatory drugs (NSAIDs, including ibuprofen, naproxen, and ASA) can directly irritate the gut lining, increase the risk of upper GI ulceration and bleeding, and in some patients precipitate IBS flares. They should not be used as a routine pain strategy for IBS. Where they are needed for an unrelated indication (musculoskeletal pain, dental pain), the lowest effective dose for the shortest necessary duration is the appropriate frame, ideally with gastroprotection in patients with IBS or ulcer history.

Opioids are an actively bad choice for IBS pain. Beyond the addiction risk and the standard opioid side-effect profile, chronic opioid use in IBS produces a syndrome called narcotic bowel syndrome, in which the gut becomes more painful over time on the medication, paradoxically driving dose escalation that worsens the underlying problem. Opioid-induced hyperalgesia is well-described in the chronic pain literature and is particularly relevant in conditions like IBS where central sensitisation is already a driver. Patients with IBS who have ended up on chronic opioids almost always benefit from a structured taper, with the gut pain often improving rather than worsening over the months following discontinuation. This is a clinical reality that runs counter to patient intuition and deserves explicit framing in any pain conversation.

What this practice offers

The clinic offers gut-directed hypnotherapy following the Manchester Protocol, delivered both virtually (across Canada) and in-person in Calgary, Alberta. The per-session fee is $220 CAD. Standard initial commitment is 3 sessions ($660 CAD total). Continuation beyond the initial 3 sessions is optional. There are no admin fees, and the price is the same virtual or in-person.

Conditions worked with include IBS (all subtypes, including IBS-D, IBS-C, IBS-M, IBS-U), SIBO as adjunct to medical treatment, functional dyspepsia, post-infectious IBS, visceral hypersensitivity, and IBS with anxiety overlap. Sessions are paid at time of service, and a detailed receipt is provided with the practitioner's ARCH registration number.

Hypnotherapy is generally not directly covered under Canadian extended health benefit plans. Some clients can claim related programs (stress management, behavioural change) under a Wellness Spending Account (WSA) if their plan offers one. Coverage rules depend entirely on plan design, so check with your insurance provider before booking.